Tresiba (Novo Nordisk) success in Quality of Life study of Type 2 Diabetes
New data from a 1-year extension trial on Tresiba (insulin degludec) show that Type 2 Diabetes patients receiving Tresiba have statistically significant better health-related quality of life compared to patients receiving insulin glargine. The data are from the BEGIN ONCE LONG trial and were presented by Novo Nordisk at the 73rd Scientific Sessions of the American Diabetes Association.
The results show that Type 2 diabetes patients receiving Tresiba reported better health-related quality of life (HRQoL) for overall physical health, which was driven by statistically significant benefits in physical functioning, such as walking and getting dressed, and less bodily pain interfering with daily activities. Also, significantly lower rates of nocturnal confirmed hypoglycaemia were observed in patients treated with Tresiba compared to those receiving insulin glargine.
see Rodbard H, et al. "Physical Health Status and Nocturnal Hypoglycaemia with Insulin Degludec vs Insulin Glargine: A 2-year Trial in Insulin-na�ve Patients with Type 2 Diabetes." Poster 934-P presentation at the 73rd Scientific Sessions of the American Diabetes Association, 22 June 2013.
Learning Zones
The Learning Zones are an educational resource for healthcare professionals that provide medical information on the epidemiology, pathophysiology and burden of disease, as well as diagnostic techniques and treatment regimens.